NICE LARC Guidelines

The National Institute for Health and Clinical Excellence (NICE) has produced guidelines on the use of long-acting reversible contraception (LARC), which includes progestogen-only contraceptive implants, progestogen-only contraceptive injections, the levonorgestrel-releasing intrauterine system and the copper intrauterine device. According to these guidelines, NICE recommends that LARC should be offered to all women as part of their contraceptive choices.^2,3

To view the NICE LARC Guidelines please visit the NICE website via the links provided below.

NICE Clinical Guidelines CG30. Long Acting Reversible Contraception: The Effective And Appropriate Use Of Long-Acting Reversible Contraception. London: NICE, 2005.

CG30 Long-Acting Reversible Contraception: Quick Reference Guide. London: NICE, 2005.

Request a visit from a Schering-Plough representative to learn more about Nexplanon, including how to train to insert and remove the contraceptive implant.

Information for the general public about the contraceptive implant, Nexplanon.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Terms and Conditions
Privacy Policy

Date of Preparation 6/2011
Code 6/12 - NEX.10.GB.9260.AVc

© 2010 Organon Laboratories Ltd trading as MSD: Registered Address: Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU.
A company registered in England and Wales. Company Registration Number: 820771